Delpino

Delpino7.5 mg

Tablet

Ivabradine

Healthcare Pharmaceuticals Ltd.

Product Code : 4548
MRP 350.00
8% Off
Best PriceTk
/
1
Section

Medicine overview

Indications of Delpino 7.5 mg

Symptomatic treatment of chronic stable angina pectoris in coronary artery disease patients with normal sinus rhythm. Delpino 7.5 mg is indicated: In patients unable to tolerate or with a contra-indication to the use of beta-blockers or In combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose and whose heart rate is > 60 bpm.

Theropeutic Class

Other Anti-anginal & Anti-ischaemic drugs

Pharmacology

Delpino 7.5 mg is a pure heart rate lowering agent. It acts by selective and specific inhibition of the cardiac pacemaker I f current that controls the spontaneous diastolic depolarization in the sinus node and regulates heart rate. By decreasing heart rate, Delpino 7.5 mg decreases the cardiac workload and therefore oxygen consumption. Concomitantly, Delpino 7.5 mg prolongs diastole allowing increased perfusion of coronary arteries and increased oxygen supply to the heart. The cardiac effects are specific to the sinus node with no effect on intra-atrial, atrioventricular or intraventricular conduction times, nor on myocardial contractility or ventricular repolarization.

Dosage & Administration of Delpino 7.5 mg

Adult: The usual recommended starting dose of Delpino 7.5 mg is 5 mg twice daily which may be increased after 3-4 weeks of treatment to 7.5 mg twice daily, depending on therapeutic response. Usual dose is 1 tablet in the morning and 1 tablet in the evening during meals. If the heart rate decreases persistently below 50 bpm at rest or if symptoms related to bradycardia, the dose must be adjusted downwards to 2.5 mg twice daily (one half of the 5 mg tablet twice daily). Treatment must be discontinued if heart rate remains below 50 bpm or symptoms of bradycardia persist.Elderly: Consider a lower starting dose (2.5 mg twice daily i.e. one half 5 mg tablet twice daily).

Dosage of Delpino 7.5 mg

Adult: The usual recommended starting dose of Delpino 7.5 mg is 5 mg twice daily which may be increased after 3-4 weeks of treatment to 7.5 mg twice daily, depending on therapeutic response. Usual dose is 1 tablet in the morning and 1 tablet in the evening during meals. If the heart rate decreases persistently below 50 bpm at rest or if symptoms related to bradycardia, the dose must be adjusted downwards to 2.5 mg twice daily (one half of the 5 mg tablet twice daily). Treatment must be discontinued if heart rate remains below 50 bpm or symptoms of bradycardia persist.Elderly: Consider a lower starting dose (2.5 mg twice daily i.e. one half 5 mg tablet twice daily).

Interaction of Delpino 7.5 mg

QT wave prolonging medicinal products is not recommended. Cardiovascular QT wave prolonging medicinal products (e.g. quinidine, disopyramide, bepridil, sotalol, ibutilide, amiodarone). Non cardiovascular QT wave prolonging medicinal products (e.g. pimozide, ziprasidone, sertindole, mefloquine, halofantrine, pentamidine, cisapride, intravenous erythromycin). The concomitant use of cardiovascular and non cardiovascular QT wave prolonging medicinal products with Delpino 7.5 mg should be avoided since QT wave prolongation may be exacerbated by heart rate reduction. If the combination appears necessary, close cardiac monitoring is needed.

Contraindications

History of hypersensitivity to Delpino 7.5 mg or any of the excipients, resting heart rate below 60 bpm before treatment, cardiogenic shock, acute myocardial infarction, severe hypotension (<90/50 mmHg), severe hepatic insufficiency, sick sinus syndrome, sino-atrial block, heart failure, pacemaker dependent, unstable angina, 3rd degree AV block, combination with strong cytochrome P-450 3A4 inhibitors (such as azole antifungals, macrolide antibiotics, HIV protease inhibitors).

Side Effects of Delpino 7.5 mg

Visual symptoms, blurred vision, bradycardia, 1st degree AV block, ventricular extrasystoles, headaches, and dizziness.

Pregnancy & Lactation

Studies in rats have shown no effect on fertility in males and females. There are no or limited amount of data from the use of Delpino 7.5 mg in pregnant women. Therefore, Delpino 7.5 mg is contra indicated during pregnancy. Animal studies indicate that Delpino 7.5 mg is excreted in milk. Therefore, Delpino 7.5 mg is contra-indicated during breast-feeding.

Precautions & Warnings

Mild to moderate hypotension, atrial fibrillation, patients with congenital QT syndrome or treated with QT wave prolonging medicinal products, Moderate hepatic insufficiency, severe renal insufficiency.

Storage Conditions

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Use In Special Populations

Renal insufficiency: Use with caution in patients with creatinine clearance Hepatic impairment: Use with caution in patients with moderate hepatic impairment; Contraindicated in severe hepatic impairment. Children and adolescents: Not recommended.

Drug Classes

Other Anti-anginal & Anti-ischaemic drugs

Mode Of Action

Delpino 7.5 mg is a pure heart rate lowering agent. It acts by selective and specific inhibition of the cardiac pacemaker I f current that controls the spontaneous diastolic depolarization in the sinus node and regulates heart rate. By decreasing heart rate, Delpino 7.5 mg decreases the cardiac workload and therefore oxygen consumption. Concomitantly, Delpino 7.5 mg prolongs diastole allowing increased perfusion of coronary arteries and increased oxygen supply to the heart. The cardiac effects are specific to the sinus node with no effect on intra-atrial, atrioventricular or intraventricular conduction times, nor on myocardial contractility or ventricular repolarization.

Pregnancy

Studies in rats have shown no effect on fertility in males and females. There are no or limited amount of data from the use of Delpino 7.5 mg in pregnant women. Therefore, Delpino 7.5 mg is contra indicated during pregnancy. Animal studies indicate that Delpino 7.5 mg is excreted in milk. Therefore, Delpino 7.5 mg is contra-indicated during breast-feeding.

Pediatric Uses

Renal insufficiency: Use with caution in patients with creatinine clearance Hepatic impairment: Use with caution in patients with moderate hepatic impairment; Contraindicated in severe hepatic impairment. Children and adolescents: Not recommended.
Disclaimer

The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.